Starting the new year with a mission to fund ovarian cancer research Friday, January 2nd, 2015 – New York, NY Amrita Singh Jewelry is proud to announce a new initiative … Continued
(December 19, 2014) The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Olaparib (Lynparza) for advanced, BRCA-mutated ovarian cancer, the first approval of a drug in the PARP (poly … Continued
When Diane Riche’s mother was diagnosed with ovarian cancer in 2010, Diane turned to the internet for information. Through her research she came to the Alliance’s website, where she learned … Continued
(12/14/14) | In 2014, with your generous support OCRF grantees made significant advances in the fight against ovarian cancer, including: Thank you for supporting our mission to fund scientific research … Continued
(December 10, 2014) OCRF Ann Schreiber Mentored Investigator Award Grantee, Pradeep Chaluvally-Raghavan, Ph.D., and other researchers at The University of Texas MD Anderson Cancer Center believe they may have found … Continued
Population-based testing for BRCA 1/2 gene mutations detects the high proportion of carriers not identified by cancer family history (FH)-based testing. A new study published in the Journal of the … Continued
One of the Ovarian Cancer National Alliance’s first Partner Members, the Ovarian Cancer Alliance of California (OCA) parallels the Alliance in many ways. Originally founded in 1998 as a chapter … Continued
A special message from OCRF Founder and Chair, Sol Schreiber.
OCRF’s 20th Anniversary Legends Gala, hosted by Harry Connick, Jr., was held on Wednesday, November 5th at The Pierre Hotel in New York City. Honorees included the Janet Burros Memorial … Continued
Genentech, a member of the Roche Group today announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with chemotherapy for the treatment of women with … Continued
The combination of the antiangiogenesis drug bevacizumab and the vascular-disrupting agent fosbretabulin is superior to bevacizumab alone in the treatment of recurrent ovarian, tubal, and peritoneal cancer, according to an … Continued
Amgen Inc said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial. Patients given the drug, trebananib, along with a chemotherapy … Continued
Get email updates about research news, action alerts, and ways to join the fight.
